University of California starts its fightback against rival Broad Institute in their dispute over intellectual property for CRISPR-Cas9.

The decision follows a review that foresaw bleak prospects for the program and little reason to invest in its development.

The cull of will see GSK focus 80% of its R&D budget on the top candidates in four therapeutic areas and potentially exit the rare disease space.

Fresh from a successful phase 1 trial for its lead asset, Kezar Life Sciences has closed a $50 million second-round funding that will help propel the…

Onconova is planning a sideways step for its lead cancer drug rigosertib—with help from a research consortium—that could open up new opportunities in rare…

The Big Pharma wants to offload six phase 2 candidates to focus its R&D dollars on a clutch of early to midstage assets.

Rodeo has got off a $5.9 million series A financing round with a list of all-stars as backers.

Monday's dose of FierceBiotech's news of note.

Celgene has announced a new arm of a phase 1b study that will study Novocure’s noninvasive brain cancer therapy alongside a pair of cancer drugs.

R&D